# Kev recommendations

#### Partnering with patients to enhance safety:

Staff must ensure that they involve, engage and listen to patients as 'partners' in their own care, including transfusion support. Engaging patients, their families, and carers as 'safety partners' helps co-create safer systems, identify, and rectify preventable adverse events



### Investing in safety - well-resourced systems with safe staffing levels:

Healthcare leaders must ensure that systems are designed to support safe transfusion practice and allocate adequate resources in clinical and laboratory areas to ensure safe staffing levels, staff training in technical and non-technical skills and appropriate equipment, including IT systems.



#### Just and learning safety culture:

All healthcare leaders must promote a just, learning safety culture with a collective, inclusive, and compassionate leadership. Effective leaders must ensure staff have access to adequate training, mentorship, and support. All staff in clinical and laboratory areas have a responsibility to speak up in case of any concerns and help embed the safety culture in teams.



**Download the SHOT App** 

SHOT Office, Manchester Blood Centre Plymouth Grove, Manchester, M13 9LL

App Store


**CONTACT DETAILS** 

www.shotuk.org

Tel: +44 (0) 161 423 4208

Enquiries: shot@nhsbt.nhs.uk

Google Play



3. SAMPLE TAKING 4. SAMPLE AND REQUEST RECEIPT 5. TESTING Critica in the 6. COMPONENT SELECTION NENT LABELLIN PONENT COLLECTION 9. PRESCRIPTION/AUTHORISATION

The 10 steps in the transfusion pathway

Risk of death and serious harm relating to transfusions in the UK in 2021

components issued.

The risk of death

related to transfusion

in the UK is 1 in 62,753

components issued

Transfusions in the UK remain very safe with low risk of harm in relation to the number of blood

The risk of transfusion-transmitted infection is much lower than

all other transfusion-related complications

-2.19 million blood components issue by the 4 UK Blood Services in 2021

Note: This is a representative image and not accurate to scale

The transfusion pathway has been updated to 10 steps to include the decision to transfuse and patient consent

Misidentification of patients is a significant cause of avoidable harm. Patient identity must be verified effectively and accurately at every step in the transfusion pathway. All staff must be aware of the importance of correct patient identification and this must be confirmed in accordance with local policies.

The risk of serious

harm related to

transfusion in the UK

is 1 in 17,431 components issued


\*Note that the pre-transfusion sample may have been taken in advance (for e.g. pre-op) while the decision to transfuse is made at a later date \*\*Once the decision to transfuse has been

made, the prescription/authorisation may be written at variable times during the sequence but must be checked at the final stage. Staff are encouraged to use the SHOT Safe Transfusion Checklist with every transfusion episode.

ABO-incompatible transfusions 2016-2021: few events (n=19) but many near misses (n=1778)




TACO pre-transfusion checklist TACO=transfusion-associated circularly overload



neview the need for trans
Can the transfusion be sa resolved?
If Proceeding with Tr
Body weight dosing for re
Transfuse a single unit (re
Measure fluid balance
Prophylactic diuretic pres
Monitor vital signs closely
Name (PRINT):
Role:
Date:
Signature:



### Paediatric SHOT summary from 2021



There were 2 deaths possibly related to transfusion, one was related to transfusionassociated necrositising enterocolitis and the other was due to transfusion delay.

Protocols must be in place for the management of massive haemorrhage in infants and children. These should include guidance on the appropriate component volumes to be used in resuscitation. Staff involved in paediatric transfusions must be fully trained to these protocols.



Hyperkalaemia is a recognised complication of large volume transfusion in neonates and infants, and 'fresh' red cells are recommended for this situation to reduce risk.

Hospitals should ensure the correct use of the paediatric red cell transfusion formula, with the Hb units in  $\alpha/L$ .

Paediatric medical and nursing education must include specific transfusion requirements for patients with haemoglobinopathies and processes must be in place to ensure these are communicated effectively to the hospital transfusion laboratories to ensure safe transfusions

To ensure safe transfusions in patients with haemoglobin disorders the following aspects need to be addressed



cell disease (SCD) patients requiring transfusion. The transfusion history, including antibody status, must be communicated between clinical and laboratory teams involved in the care of the patient. This should include any specialist tests from reference laboratories.



Individual transfusion decisions in SCD patients can be challenging, and advice from haemoglobinopathy specialists is recommended.



For patients with complex transfusion requirements, a multidisciplinary approach is recommended with representation from haemoglobinopathy experts and transfusion medicine specialists. Where possible, a transfusion plan should be agreed in advance of an anticipated transfusion.



A detailed transfusion history must be obtained in all sickle





**19** ABO-incompatible red cell transfusions

1778 ABO-incompatible near miss events

**Serious Hazards** of Transfusion ANNUAL SHOT

REPORT

SUMMARY

2021

ent Risk Assessment		YES	NO
s the patient have any of the following: diagnosis eart failure', congestive cardiac failure (CCF), severe aortic osis, or moderate to severe left ventricular dysfunction?			
e patient on a regular diureti	c?		
s the patient have severe anaemia?			
e patient known to have pul	monary oedema?		
s the patient have respiratory symptoms of agnosed cause?			
e fluid balance clinically sign	ificantly positive?		
e patient receiving intravenous fluids ceived them in the previous 24 hours)?			
ere any peripheral oedema?			
s the patient have hypoalbuminaemia?			
s the patient have significant renal impairment?			
		YES	NO
fusion (do the benefits outweigh the risks)?			
fely deferred until the issue is investigated, treated or			
ansfusion: Assign Actio	ns		TICK
ed cells			
d cells) and review sympton	าร		
cribed			
, including oxygen saturatio	n		
	Due to the differences in adult and neonatal		



siology, babies may have a different risk for TACO. Calculate the dose by weight and observe the notes above.

# PARTNERING WITH PATIENTS TO ENHANCE TRANSFUSION SAFETY





#### Distribution of anti-D lg related error reports in 2021 (n=341)

#### 228 Omission or late administration of anti-D lo Anti-D Ig given to the mother of a D-negative infant 50 Anti-D Ig given to a woman with immune anti-D 16 Anti-D Ig given to a D-positive woman 15 11 Anti-D Ig handling and storage errors 10 Miscellaneous Wrong dose of anti-D Ig given 10 Anti-D Ig given to the wrong woman

Note: Miscellaneous cases included 4 failures to complete follow up post FMH greater than 4mL, and 6 failures in sample taking or testing processes

#### Summary data for 2021, all categories (includes RBRP and NM) n=3161

Errors account for most reports:


Errors

2569 Errors (all preventable)

205 Possibly preventable

387 Not preventable

2569/3161



Delayed transfusion reports and deaths by year 2011 to

2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021

179

133 129


2021 (n=952, deaths n=61)

Total cases

Deaths


# Transfusion-related deaths 2010-2021 n=247


TACO and delays are the most prevalent causes of transfusion-related deaths year on year.




TRALI=transfusion-related acute lung injury; TACO=transfusion-associated circulatory overload; TAD=transfusion-associated dyspnoea; HTR=haemolytic transfusion reaction; FAHR=febrile, allergic and hypotensive reactions


Delays include 1 delay due to PCC in 2019; HTR includes 2 deaths due to ABO-incompatibility; 'Other' includes 1 each for post-transfusion purpura, transfusion-associated graft-versus-host disease (2012) and anti-D lg related; there were 8 in the avoidable, over or undertransfusion category, 3 transfusion-transmitted infections, and 12 deaths related to other unclassified reactions








Preventable deaths n=16/35 (45.7%)





## Deaths related to transfusion (with imputability) reported in 2021 n=35

HTF



### Key laboratory recommendations